Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Disagreement between Human Papillomavirus Assays : An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening. / Rebolj, Matejka; Preisler, Sarah; Ejegod, Ditte Møller; Rygaard, Carsten; Lynge, Elsebeth; Bonde, Jesper.

In: PLOS ONE, Vol. 9, No. 1, e86835, 01.2014, p. 1-12.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Rebolj, M, Preisler, S, Ejegod, DM, Rygaard, C, Lynge, E & Bonde, J 2014, 'Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening', PLOS ONE, vol. 9, no. 1, e86835, pp. 1-12. https://doi.org/10.1371/journal.pone.0086835

APA

Rebolj, M., Preisler, S., Ejegod, D. M., Rygaard, C., Lynge, E., & Bonde, J. (2014). Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening. PLOS ONE, 9(1), 1-12. [e86835]. https://doi.org/10.1371/journal.pone.0086835

Vancouver

Rebolj M, Preisler S, Ejegod DM, Rygaard C, Lynge E, Bonde J. Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening. PLOS ONE. 2014 Jan;9(1):1-12. e86835. https://doi.org/10.1371/journal.pone.0086835

Author

Rebolj, Matejka ; Preisler, Sarah ; Ejegod, Ditte Møller ; Rygaard, Carsten ; Lynge, Elsebeth ; Bonde, Jesper. / Disagreement between Human Papillomavirus Assays : An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening. In: PLOS ONE. 2014 ; Vol. 9, No. 1. pp. 1-12.

Bibtex

@article{a868b79f08c84f53814e30837b46186a,
title = "Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening",
abstract = "We aimed to determine the disagreement in primary cervical screening between four human papillomavirus assays: Hybrid Capture 2, cobas, CLART, and APTIMA. Material from 5,064 SurePath samples of women participating in routine cervical screening in Copenhagen, Denmark, was tested with the four assays. Positive agreement between the assays was measured as the conditional probability that the results of all compared assays were positive given that at least one assay returned a positive result. Of all 5,064 samples, 1,679 (33.2{\%}) tested positive on at least one of the assays. Among these, 41{\%} tested positive on all four. Agreement was lower in women aged ≥ 30 years (30{\%}, vs. 49{\%} at <30 years), in primary screening samples (29{\%}, vs. 38{\%} in follow-up samples), and in women with concurrent normal cytology (22{\%}, vs. 68{\%} with abnormal cytology). Among primary screening samples from women aged 30-65 years (n = 2,881), 23{\%} tested positive on at least one assay, and 42 to 58{\%} of these showed positive agreement on any compared pair of the assays. While 4{\%} of primary screening samples showed abnormal cytology, 6 to 10{\%} were discordant on any pair of assays. A literature review corroborated our findings of considerable disagreement between human papillomavirus assays. This suggested that the extent of disagreement in primary screening is neither population- nor storage media-specific, leaving assay design differences as the most probable cause. The substantially different selection of women testing positive on the various human papillomavirus assays represents an unexpected challenge for the choice of an assay in primary cervical screening, and for follow up of in particular HPV positive/cytology normal women.",
keywords = "Adult, Aged, Biological Assay, Denmark, Early Detection of Cancer, Female, Humans, Mass Screening, Middle Aged, Papillomaviridae, Papillomavirus Infections, Young Adult",
author = "Matejka Rebolj and Sarah Preisler and Ejegod, {Ditte M{\o}ller} and Carsten Rygaard and Elsebeth Lynge and Jesper Bonde",
year = "2014",
month = "1",
doi = "10.1371/journal.pone.0086835",
language = "English",
volume = "9",
pages = "1--12",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

RIS

TY - JOUR

T1 - Disagreement between Human Papillomavirus Assays

T2 - An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening

AU - Rebolj, Matejka

AU - Preisler, Sarah

AU - Ejegod, Ditte Møller

AU - Rygaard, Carsten

AU - Lynge, Elsebeth

AU - Bonde, Jesper

PY - 2014/1

Y1 - 2014/1

N2 - We aimed to determine the disagreement in primary cervical screening between four human papillomavirus assays: Hybrid Capture 2, cobas, CLART, and APTIMA. Material from 5,064 SurePath samples of women participating in routine cervical screening in Copenhagen, Denmark, was tested with the four assays. Positive agreement between the assays was measured as the conditional probability that the results of all compared assays were positive given that at least one assay returned a positive result. Of all 5,064 samples, 1,679 (33.2%) tested positive on at least one of the assays. Among these, 41% tested positive on all four. Agreement was lower in women aged ≥ 30 years (30%, vs. 49% at <30 years), in primary screening samples (29%, vs. 38% in follow-up samples), and in women with concurrent normal cytology (22%, vs. 68% with abnormal cytology). Among primary screening samples from women aged 30-65 years (n = 2,881), 23% tested positive on at least one assay, and 42 to 58% of these showed positive agreement on any compared pair of the assays. While 4% of primary screening samples showed abnormal cytology, 6 to 10% were discordant on any pair of assays. A literature review corroborated our findings of considerable disagreement between human papillomavirus assays. This suggested that the extent of disagreement in primary screening is neither population- nor storage media-specific, leaving assay design differences as the most probable cause. The substantially different selection of women testing positive on the various human papillomavirus assays represents an unexpected challenge for the choice of an assay in primary cervical screening, and for follow up of in particular HPV positive/cytology normal women.

AB - We aimed to determine the disagreement in primary cervical screening between four human papillomavirus assays: Hybrid Capture 2, cobas, CLART, and APTIMA. Material from 5,064 SurePath samples of women participating in routine cervical screening in Copenhagen, Denmark, was tested with the four assays. Positive agreement between the assays was measured as the conditional probability that the results of all compared assays were positive given that at least one assay returned a positive result. Of all 5,064 samples, 1,679 (33.2%) tested positive on at least one of the assays. Among these, 41% tested positive on all four. Agreement was lower in women aged ≥ 30 years (30%, vs. 49% at <30 years), in primary screening samples (29%, vs. 38% in follow-up samples), and in women with concurrent normal cytology (22%, vs. 68% with abnormal cytology). Among primary screening samples from women aged 30-65 years (n = 2,881), 23% tested positive on at least one assay, and 42 to 58% of these showed positive agreement on any compared pair of the assays. While 4% of primary screening samples showed abnormal cytology, 6 to 10% were discordant on any pair of assays. A literature review corroborated our findings of considerable disagreement between human papillomavirus assays. This suggested that the extent of disagreement in primary screening is neither population- nor storage media-specific, leaving assay design differences as the most probable cause. The substantially different selection of women testing positive on the various human papillomavirus assays represents an unexpected challenge for the choice of an assay in primary cervical screening, and for follow up of in particular HPV positive/cytology normal women.

KW - Adult

KW - Aged

KW - Biological Assay

KW - Denmark

KW - Early Detection of Cancer

KW - Female

KW - Humans

KW - Mass Screening

KW - Middle Aged

KW - Papillomaviridae

KW - Papillomavirus Infections

KW - Young Adult

U2 - 10.1371/journal.pone.0086835

DO - 10.1371/journal.pone.0086835

M3 - Journal article

C2 - 24466262

VL - 9

SP - 1

EP - 12

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 1

M1 - e86835

ER -

ID: 135653898